Nanoparticle-Based Chemotherapy Formulations for Head and Neck Cancer: A Systematic Review and Perspectives.
Nanoparticle-Based Chemotherapy Formulations for Head and Neck Cancer: A Systematic Review and Perspectives.
复制标题
DOI：
10.3390/nano10101938
复制
发表时间：
2020-09-29
期刊：
影响因子：
--
通讯作者：
da Silva SD
中科院分区：
文献类型：
--
作者：
de Lima JM;Bonan PR;da Cruz Perez DE;Hier M;Alaoui-Jamali MA;da Silva SD
头颈部癌是一种复杂的异质性疾病，在世界范围内具有高死亡率和高发病率。晚期HNC的标准治疗管理（通常基于放疗与化疗的组合）受到严重的长期副作用的阻碍。为了克服这些副作用，肿瘤选择性纳米颗粒已被开发作为一种潜在的药物递送系统，以改善HNC治疗。本系统性综述使用了MEDLINE、EMBASE、科克伦口腔健康组试验注册库、科克伦对照试验中心注册库（CENTRAL）和ClinicalTrials.gov（从开始到2020年6月）的组合。共审查了1747篇已发表的手稿，检索了9篇相关参考文献进行分析，其中8篇符合荟萃分析的条件。基于这些研究，关于纳米制剂用于HNC治疗对肿瘤缓解和不良副作用（SAE）的疗效的证据水平较低。尽管基础研究已经揭示了纳米材料在改善癌症治疗结果方面的更大前景，但它们都没有转化为HNC患者的临床益处。本文综述了近年来靶向纳米粒子治疗HNC的研究进展，并展望了其发展前景。
Head and neck cancer (HNC) is a complex and heterogeneous disease associated with high mortality and morbidity worldwide. Standard therapeutic management of advanced HNC, which is based on radiotherapy often combined with chemotherapy, has been hampered by severe long-term side effects. To overcome these side effects, tumor-selective nanoparticles have been exploited as a potential drug delivery system to improve HNC therapy. A combination of MEDLINE, EMBASE, Cochrane Oral Health Group’s Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.gov from inception up to June 2020 was used for this systematic review. A total of 1747 published manuscripts were reviewed and nine relevant references were retrieved for analysis, while eight of them were eligible for meta-analysis. Based on these studies, the level of evidence about the efficacy of nanoformulation for HNC therapy on tumor response and adverse side effects (SAE) was low. Even though basic research studies have revealed a greater promise of nanomaterial to improve the outcome of cancer therapy, none of them were translated into clinical benefits for HNC patients. This systematic review summarized and discussed the recent progress in the development of targeted nanoparticle approaches for HNC management, and open-up new avenues for future perspectives.
登录
查看更多内容
影响因子：
3.8
作者：
Miller K;Cortes J;Hurvitz SA;Krop IE;Tripathy D;Verma S;Riahi K;Reynolds JG;Wickham TJ;Molnar I;Yardley DA
通讯作者：
Yardley DA
影响因子：
8.9
作者：
Marur, Shanthi;Forastiere, Arlene A.
通讯作者：
Forastiere, Arlene A.
影响因子：
50.5
作者：
Caponigro, F;Comella, P;Comella, G
通讯作者：
Comella, G
影响因子：
17.4
作者：
Hassan S;Prakash G;Ozturk A;Saghazadeh S;Sohail MF;Seo J;Dockmeci M;Zhang YS;Khademhosseini A
通讯作者：
Khademhosseini A
影响因子：
6.4
作者：
Carvalho, AL;Nishimoto, IN;Kowalski, LP
通讯作者：
Kowalski, LP